Cost-Benefit Analysis of Newer versus Older Antidepressants

Changes in the social and health services over the last years have forced doctors to concern themselves with cost benefit calculations and budget forecasting. Cost considerations are a (co-) determinant in the choice of antidepressants as well as neuroleptics and/or antipsychotics. In recent years, pharmacoeconomic studies have been performed to answer the question as to what extent treatment with new antidepressants, in particular SSRIs, is actually less expensive than treatment with (generic) tricyclic antidepressants due to better safety profiles and higher compliance in spite of the considerably higher retail price. Following descriptions of the methodological principles, the currently available studies are presented and discussed critically in this report. It can be stated that the economic value of different antidepressants can not be decided definitively at the present time. The available data do not allow the conclusion that SSRIs should be preferred over tricyclic antidepressants with the argument that the treatment as a whole is more cost effective in spite of the higher costs.

References

• 1 Anderson I M, Tomenson B M. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis.  BMJ. 1995;  310 1433-1438
• 2 Boyer P, Danion J M, Bisserbe J C. et al . Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in a primary-care setting in France.  Pharmacoeconomics. 1998;  13 157-169
• 3 Crott R, Gilis P. Economic comparisons of the pharmacotherapy of depression: an overview.  Acta Psychiatr Scand. 1998;  97 241-252
• 4 Crown W H, Hylan T R, Meneades L. Antidepressant selection and use and healthcare expenditures.  Pharmacoeconomics. 1998;  13 435-448
• 5 Einarson T R, Arikian S, Sweeney S. et al . A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders.  Clin Ther. 1995;  17 136-153
• 6 Forder J, Kavanagh S, Fenyo A. A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care.  J Affect Disord. 1996;  38 97-111
• 7 Freemantle N, House A, Song F. et al . Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide.  BMJ. 1994;  309 249-253
• 8 Fritze J. Kosten-Nutzen-Relation von Antidepressiva.  Münch med Wschr. 1997;  139 481-483
• 9 Henry J A, Rivas C A. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use.  Pharmacoeconomics. 1997;  11 515-537
• 10 Holm K J, Iarvis B, Foster R H. Mirtazapine. A pharmacoeconomic review of its use in depression.  Pharmacoeconomics. 2000;  17 515-534
• 11 Hotopf M, Lewis G, Normand C. Are SSRIs a cost-effective alternative to tricyclics?.  Brit J Psychiatry. 1996;  168 404-409
• 12 Hylan T R, Crown W H, Meneades L, Heiligenstein J H. et al . Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis.  J Affect Disord. 1998;  47 71-79
• 13 Johnson R E, McFarland B H, Nichols G A. Changing patterns of antidepressant use and costs in a health maintenance organisation.  Pharmacoeconomics. 1997;  11 274-286
• 14 Jönsson B, Bebbington P E. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment.  Brit J Psychiatry. 1994;  164 665-673
• 15 Lapierre Y, Bentkover J, Schainbaum S. et al . Direct costs of depression: analysis of treatment costs of paroxetine versus imipramine in Canada.  Can J Psychiatry. 1995;  40 370-377
• 16 Lave J R, Frank G, Schulberg H C, Kamlet M S. Cost-effectiveness of treatments for major depression in primary care practice.  Arch Gen Psychiatry. 1998;  55 645-651
• 17 Le Pen C, Levy E, Ravily V, Beuzen J N. et al . The cost of treatment dropout in depression. A cost-benefit analysis of fluoxetine vs. tricyclics.  J Affect Disord. 1994;  31 1-18
• 18 Martin R M, Hilton S R, Kerry S M, Richards N M. General practitioners' perceptions of the tolerability of antidepressant drugs: a comparison of selective serotonin reuptake inhibitors and tricyclic antidepressants.  BMJ. 1997;  314 646-651
• 19 Montgomery S A, Brown R E, Clark M. Economic analysis of treating depression with nefazodone versus imipramine.  Brit J Psychiatry. 1996;  168 768-771
• 20 Nuijten M J C, Hardens M, Soutre E. A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression.  Pharmacoeconomics. 1995;  8 159-168
• 21 Priest R G. Cost-effectiveness of venlafaxine for the treatment of major depression in hospitalized patients.  Clin Ther. 1996;  18 2-9
• 22 Revicki D A, Brown R E, Keller M B. et al . Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings.  J Clin Psychiatry. 1997;  58 47-58
• 23 Rice D P, Miller L S. Health economics and cost implications of anxiety and other mental disorders in the United States.  Brit J Psychiatry. 1998;  173 (suppl. 34) 4-9
• 24 Rössler G, Kirch W. Medizin und Gesundheitswissenschaften. Beiträge der Public-Health-Forschung zur medizinischen Praxis.  Internist prax. 1998;  38 697-705
• 25 Sclar D A, Robison L M, Skaer T L. et al . Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization.  J Int Med Res. 1995;  23 395-412
• 26 Sclar D, Skaer T L, Robison L M, Galin R S. et al . Economic outcomes with antidepressant pharmacotherapy: A retrospective intent-to-treat analysis.  J Clin Psychiatry. 1998;  59 (Suppl. 2) 13-17
• 27 Simon G E, Fishman P. Cost implications of initial antidepressant selection in primary care.  Pharmacoeconomics. 1998;  13 61-70
• 28 Skaer T L, Sclar D A, Robison L M. et al . Economic evaluation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression.  Curr Ther Res. 1995;  56 556-567
• 29 Song F, Freemantle N, Sheldon T A. et al . Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability.  Brit Med J. 1983;  306 683-687
• 30 Stewart A. Choosing an antidepressant: effectiveness based pharmacoeconomics.  J Affect Disord. 1998;  48 125-133
• 31 Wilde M I, Benfield P. Fluoxetine. A pharmacoeconomic review of its use in depression.  Pharmacoeconomics. 1998;  13 543-561
• 32 Woods S W, Baker C B. Cost-effectiveness of newer antidepressants.  Current Opinion in Psychiatry. 1997;  10 95-101
• 33 Woods S W, Rizzo J A. Cost-effectiveness of antidepressant treatment reassessed.  Brit J Psychiatry. 1997;  170 257-263